Yi Soong

TL;DR: Overproduction of ROS underlies the cellular toxicity of tBHP and 3NP, and ROS mediate cytochrome c release via MPT, and these IMM-targeted antioxidants may be very beneficial in the treatment of aging and diseases associated with oxidative stress.

TL;DR: SS-31, which is currently in clinical trials for ischemia-reperfusion injury, protects mitochondrial cristae by interacting with cardiolipin on the inner mitochondrial membrane, and inhibited cytochrome c peroxidase activity.

TL;DR: Treatment with SS-31 protected mitochondrial structure and respiration during early reperfusion, accelerated recovery of ATP, reduced apoptosis and necrosis of tubular cells, and abrogated tubular dysfunction, suggesting that it may protect against ischemic renal injury.

TL;DR: Dramatic changes in mitochondrial structure in glomerular endothelial cells, podocytes, and proximal tubular epithelial cells are reported after 28 weeks of a high-fat diet in C57BL/6 mice, indicating mitochondria protection can overcome lipotoxicity in the kidney and represent a novel upstream target for therapeutic development.

TL;DR: This study shows that pretreatment with both SS-31 and SS-20 significantly reduced myocardial lipid peroxidation and infarct size in ischemia–reperfusion injury, and suggests that the cardioprotective properties of 2′,6′-dimethyl-tyrosine-D-Arg-Phe-Lys-NH2 was primarily mediated by its antioxidant properties.